东北制药
(000597)
| 流通市值：79.77亿 | | | 总市值：80.77亿 |
| 流通股本：14.09亿 | | | 总股本：14.27亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,478,085,124.55 | 3,852,608,126.41 | 1,947,277,598.78 | 7,502,554,909.23 |
| 营业收入 | 5,478,085,124.55 | 3,852,608,126.41 | 1,947,277,598.78 | 7,502,554,909.23 |
| 二、营业总成本 | 5,196,594,704.99 | 3,627,698,065.72 | 1,828,004,577.99 | 6,888,697,612.66 |
| 营业成本 | 3,559,122,924.57 | 2,515,169,386.75 | 1,283,000,859.34 | 4,596,466,279.52 |
| 税金及附加 | 54,467,926.5 | 36,400,771.14 | 17,337,637.15 | 77,341,554.24 |
| 销售费用 | 879,243,019.69 | 625,114,853.86 | 307,273,222.11 | 1,381,892,380.61 |
| 管理费用 | 590,775,568.39 | 382,332,472.58 | 196,073,967.25 | 741,452,499.9 |
| 研发费用 | 103,963,842.54 | 71,797,472.56 | 31,999,540.39 | 117,763,982.51 |
| 财务费用 | 9,021,423.3 | -3,116,891.17 | -7,680,648.25 | -26,219,084.12 |
| 其中:利息费用 | 35,733,492.89 | 24,069,106.24 | 11,720,485.46 | 64,533,460.27 |
| 其中:利息收入 | 63,805,443.01 | 46,496,461.42 | 24,526,792.86 | 128,628,643.84 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 373,669.04 | - | - | - |
| 加:投资收益 | 8,414,313.69 | 2,871,681.33 | 1,350,929.69 | 5,160,420.26 |
| 资产处置收益 | 748,033.03 | 181,512.23 | 8,990.07 | 6,192,436.61 |
| 资产减值损失(新) | -91,448,958.62 | -90,837,948.21 | -64,439,253.74 | -125,566,328.87 |
| 信用减值损失(新) | -395,965.12 | -2,793,579.23 | -5,872,091.65 | 2,544,051.19 |
| 其他收益 | 72,011,551.68 | 59,793,951.43 | 25,452,646.61 | 75,573,520.7 |
| 四、营业利润 | 271,193,063.26 | 194,125,678.24 | 75,774,241.77 | 577,761,396.46 |
| 加:营业外收入 | 10,976,989.74 | 4,427,705.87 | 1,812,944.94 | 48,519,028.2 |
| 减:营业外支出 | 42,340,293.45 | 20,908,559.62 | 11,510,920.82 | 32,370,037.1 |
| 五、利润总额 | 239,829,759.55 | 177,644,824.49 | 66,076,265.89 | 593,910,387.56 |
| 减:所得税费用 | 78,785,148.6 | 53,382,106 | 30,704,850.96 | 170,628,065.67 |
| 六、净利润 | 161,044,610.95 | 124,262,718.49 | 35,371,414.93 | 423,282,321.89 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 161,044,610.95 | 124,262,718.49 | 35,371,414.93 | 423,282,321.89 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 172,703,081.21 | 129,178,610.43 | 36,321,572.23 | 409,848,498.88 |
| 少数股东损益 | -11,658,470.26 | -4,915,891.94 | -950,157.3 | 13,433,823.01 |
| 扣除非经常损益后的净利润 | 132,146,529.56 | 89,357,384.72 | 19,906,997.48 | 311,652,391.31 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.12 | 0.09 | 0.03 | 0.29 |
| (二)稀释每股收益 | 0.12 | 0.09 | 0.03 | 0.29 |
| 八、其他综合收益 | -506,469.98 | -167,773.2 | -58,468.97 | 629,692.33 |
| 归属于母公司股东的其他综合收益 | -508,681.3 | -168,568.1 | -58,741.05 | 632,527.83 |
| 九、综合收益总额 | 160,538,140.97 | 124,094,945.29 | 35,312,945.96 | 423,912,014.22 |
| 归属于母公司股东的综合收益总额 | 172,194,399.91 | 129,010,042.33 | 36,262,831.18 | 410,481,026.71 |
| 归属于少数股东的综合收益总额 | -11,656,258.94 | -4,915,097.04 | -949,885.22 | 13,430,987.51 |
| 公告日期 | 2025-10-28 | 2025-08-27 | 2025-04-29 | 2025-04-03 |
| 审计意见(境内) | | | | 标准无保留意见 |